Prostamax (20MG)

What Is Prostamax?

Prostamax is a synthetic tetrapeptide bioregulator with the amino acid sequence Lys-Glu-Asp-Pro (KEDP). It belongs to the Khavinson peptide series—a family of short-chain peptides developed through research on tissue-specific bioregulators at the St. Petersburg Institute of Bioregulation and Gerontology. Researchers originally derived Prostamax from prostate tissue extracts and designed it as a synthetic analog for investigating prostate tissue function and gene regulation.

As a tetrapeptide—a peptide composed of exactly four amino acids—Prostamax has attracted research interest for its proposed ability to interact with nuclear components including DNA and histones, thereby modulating gene expression through epigenetic mechanisms. Researchers classify Prostamax as a peptide bioregulator, meaning it may influence cellular processes through chromatin remodeling and transcriptional regulation rather than through classical receptor-mediated signaling. For those looking to buy Prostamax in Switzerland, Core Peptides offers high-quality research-grade material for laboratory applications.

Prostamax Research Overview

Prostamax represents a well-characterized peptide bioregulator within the Khavinson research program. The peptide’s design—a simple tetrapeptide sequence of lysine, glutamic acid, aspartic acid, and proline—belies its proposed biological activity. Researchers have investigated Prostamax primarily for its tissue-specific effects on prostate-derived experimental systems, with implications for understanding gene expression regulation, chromatin structure, and age-related cellular changes.

Research interest in Prostamax centers on its ability to modulate chromatin structure and gene expression in prostate tissue. Studies have demonstrated that Prostamax induces chromatin decondensation, reactivates genes repressed during aging, and influences cellular function in prostate-derived cell populations. Consequently, Prostamax has generated significant interest as a research tool for investigating tissue-specific gene regulation, epigenetic mechanisms, and age-related cellular changes.

When researchers choose to buy Prostamax in Switzerland for laboratory studies, they gain access to a compound that may help elucidate mechanisms of prostate tissue bioregulation, chromatin remodeling, and gene expression at the molecular level.

How Does Prostamax Work?

The proposed mechanism of Prostamax involves multiple interconnected pathways, including chromatin remodeling, epigenetic regulation, and tissue-specific gene modulation.

Chromatin Remodeling and Deheterochromatinization

Prostamax’s primary mechanism involves selective relaxation of heterochromatin—a process called deheterochromatinization. Research has shown that Prostamax induces chromatin decondensation and deheterochromatinization, potentially reactivating genes repressed during aging. The peptide increases the frequency of sister chromatid exchanges and Ag-positive nucleolar organizer regions (NORs), while reducing large segments of pericentromeric heterochromatin.

In a 2004 study, researchers compared five Khavinson peptides (Vilon, Epithalon, Livagen, Prostamax, and Cortagen) in leukocytes from donors aged 75-88 years. All five peptides induced activation of ribosomal genes, decondensation of densely packed chromatin fibers, and release of genes suppressed by age-specific euchromatin region compression. Prostamax specifically induced decondensation of pericentromeric heterochromatin of chromosome 1.

Epigenetic Regulation and Gene Expression

Prostamax is thought to regulate gene expression through epigenetic mechanisms mediated by direct interactions between the peptide and nuclear components including DNA and histones. Within the Khavinson model, peptides of this class are proposed to act at the chromatin level to modulate tissue-specific gene-expression patterns in experimental aging models.

Furthermore, Prostamax appears to reverse age-related chromatin condensation selectively in prostate tissue, allowing normally silenced genes to activate. This mechanism supports the peptide’s tissue-specific effects on prostate-derived experimental systems.

Tissue-Specific Gene Regulation

Prostamax is studied as a prostate-tissue-directed short-peptide probe, used to examine how a minimal defined peptide signal influences transcriptional, proteomic, and proliferation/apoptosis endpoints in prostate-derived cell populations. In organotypic explant culture, KEDP has been reported to act tissue-specifically on prostate explants.

Researchers who buy Prostamax in Switzerland for research purposes can investigate these mechanisms across diverse experimental models of tissue-specific gene regulation and epigenetic modulation.

Why Is Prostamax Studied?

Researchers study Prostamax primarily for its potential relevance to prostate tissue biology, gene expression regulation, and age-related cellular changes. The peptide’s ability to modulate chromatin structure and gene expression makes it a valuable tool for understanding the molecular basis of tissue-specific bioregulation and epigenetic mechanisms.

The peptide’s connection to the Khavinson bioregulator program has made it a focus of prostate and epigenetic research. Preclinical studies have explored Prostamax’s effects on chromatin structure, gene expression, and cellular function in various experimental models, including prostate-derived cell populations, organotypic explant cultures, and aged rodent models.

Moreover, researchers study Prostamax in the context of age-related cellular changes and tissue-specific gene regulation. As chromatin structure and gene expression patterns change with age, understanding mechanisms that support normal tissue function has become increasingly important. Prostamax represents one well-documented avenue of research inquiry in this area.

Researchers who buy Prostamax in Switzerland from Core Peptides can incorporate this peptide into their studies on prostate tissue bioregulation, chromatin remodeling, epigenetic regulation, and age-related gene expression.

Prostamax Research Areas

Research Area	Description
Chromatin Remodeling	Investigating Prostamax’s ability to induce chromatin decondensation and deheterochromatinization
Prostate Tissue Gene Expression	Studying Prostamax’s effects on tissue-specific gene regulation in prostate-derived systems
Epigenetic Regulation	Examining Prostamax’s interaction with DNA, histones, and epigenetic mechanisms
Age-Related Gene Reactivation	Exploring Prostamax’s potential to reactivate genes repressed during aging
Ribosomal Gene Transcription	Investigating Prostamax’s effects on nucleolar organizer regions and rRNA gene activation
Sister Chromatid Exchange	Studying Prostamax’s influence on chromosomal stability and recombination
Prostate Tissue Bioregulation	Preclinical research into Prostamax’s tissue-specific effects on prostate explants
Cellular Senescence	Exploring Prostamax’s potential relevance to age-related cellular changes

Scientific Research on Prostamax

Researchers have conducted scientific studies on Prostamax in both in vitro and ex vivo settings, deriving evidence from cell cultures, organotypic explant cultures, and preclinical models. The peptide originates from the Khavinson research program, which has investigated tissue-specific peptide bioregulators for several decades.

In Vitro Evidence

In vitro studies have demonstrated that Prostamax induces chromatin decondensation and activates ribosomal gene transcription in lymphocytes from older donors. A 2004 study reported that Prostamax incubation reactivates constitutive heterochromatin and rRNA-gene transcription in peripheral-blood lymphocytes of donors aged 60-79 years.

Furthermore, research has shown that Prostamax increases the frequency of sister chromatid exchanges and Ag-positive nucleolar organizer regions (NORs), while reducing large segments of pericentromeric heterochromatin. These changes promote chromatin decondensation and deheterochromatinization, potentially reactivating genes repressed during aging.

Ex Vivo and Organotypic Studies

In organotypic explant culture, KEDP has been reported to act tissue-specifically on prostate explants. This tissue-specific activity supports the proposed role of Prostamax as a prostate-directed bioregulator. Research has also explored Prostamax’s effects on prostate tissue in aged rat models, demonstrating reduced inflammation and pathological remodeling.

Human Research

Prostamax has limited human clinical evidence. The single PubMed-indexed canonical citation for Prostamax is the 2004 study by Khavinson and colleagues. The peptide has not been tested in human clinical trials, and no clinical trials are registered on ClinicalTrials.gov. All published research originates from the Khavinson research network, and independent replication remains a chief gap. Scientists who buy Prostamax in Switzerland should remain aware of these evidence considerations.

Prostamax Compared With Related Peptides

Peptide	Relationship to Prostamax	Key Differences
Vesugen (KED)	Shares the N-terminal three residues of Prostamax	Vesugen is a tripeptide (Lys-Glu-Asp) targeting vascular-endothelial tissue; Prostamax (KEDP) targets prostate tissue
Pancragen (KEDW)	Shares the KED core sequence	Pancragen has tryptophan at C-terminus targeting pancreatic tissue; Prostamax has proline targeting prostate tissue
Livagen (KEDA)	Shares the KED core sequence	Livagen has alanine at C-terminus targeting liver tissue; Prostamax has proline
Vilon (KE)	Shares the first two residues	Vilon is a dipeptide (Lys-Glu) targeting thymus/immune system; Prostamax is a tetrapeptide
Epithalon (AEDG)	Same Khavinson peptide series	Epithalon targets pineal gland and circadian rhythms; Prostamax targets prostate tissue

Research Applications

Researchers utilize Prostamax in a variety of laboratory research applications, primarily in the fields of epigenetics, prostate biology, and tissue-specific gene regulation. Key research applications include:

• Chromatin Remodeling Studies: Investigating Prostamax’s ability to induce chromatin decondensation and deheterochromatinization
• Prostate Tissue Gene Expression Research: Studying Prostamax’s effects on tissue-specific gene regulation in prostate-derived systems
• Epigenetic Regulation Studies: Examining Prostamax’s interaction with DNA, histones, and epigenetic mechanisms
• Age-Related Gene Reactivation Research: Exploring Prostamax’s potential to reactivate genes repressed during aging
• Ribosomal Gene Transcription Studies: Investigating Prostamax’s effects on nucleolar organizer regions and rRNA gene activation
• Sister Chromatid Exchange Research: Studying Prostamax’s influence on chromosomal stability and recombination
• Prostate Tissue Bioregulation Studies: Preclinical research into Prostamax’s tissue-specific effects on prostate explants
• Cellular Senescence Research: Exploring Prostamax’s potential relevance to age-related cellular changes

Researchers who buy Prostamax in Switzerland can incorporate this peptide into their experimental protocols across these diverse research areas.

Prostamax Product Specifications

Specification	Detail
Product Name	Prostamax (KEDP peptide)
Amount	20mg
Form	Lyophilized powder
Sequence (Three-Letter)	Lys-Glu-Asp-Pro (KEDP)
Sequence (One-Letter)	KEDP
Molecular Formula	C20H33N5O9
Molecular Weight	Approximately 487.50 g/mol
CAS Number	Not assigned in public literature
PubChem CID	9848296
Synonyms	KEDP, Lys-Glu-Asp-Pro, prostate peptide bioregulator
Purity	≥ 99% (HPLC)
Research Category	Cellular Research & Signaling
Storage	Store at -20°C, desiccated, protected from light

How to Evaluate Prostamax Quality

When sourcing Prostamax for research purposes, researchers should consider several quality indicators. A reliable Prostamax peptide supplier should provide:

• Identity Confirmation: Analytical verification that the peptide matches the expected sequence (Lys-Glu-Asp-Pro, KEDP) and molecular weight (approximately 487.50 g/mol)
• Purity Analysis: Documentation of purity through methods such as HPLC (High-Performance Liquid Chromatography) – Core Peptides provides ≥99% purity
• Batch Information: Clear lot numbers and batch traceability
• Certificate of Analysis (CoA): Documentation of analytical testing results
• Proper Labeling: Accurate product identification and storage instructions
• Appearance: White to off-white lyophilized powder

Researchers looking to buy Prostamax in Switzerland should seek suppliers who provide comprehensive documentation and quality assurance. Core Peptides remains committed to supporting research with properly documented products.

Understanding the Certificate of Analysis

A Certificate of Analysis (CoA) provides analytical data for a specific batch of a research peptide. For Prostamax research, a CoA typically includes:

• Identity Confirmation: Mass spectrometry or other analytical methods confirming the peptide’s identity
• Purity Assessment: HPLC chromatograms showing the purity of the peptide
• Batch/Lot Information: Unique identifiers for traceability
• Analytical Methods: Description of the testing methods used

Importantly, researchers should understand that a CoA demonstrates the chemical identity and purity of a peptide but does not establish safety, efficacy, therapeutic effectiveness, or suitability for human use. The CoA serves as a quality control document for research purposes only.

Storage and Stability

Proper storage of research peptides is essential for maintaining their integrity and stability. For Prostamax, researchers should store the lyophilized peptide at -20°C or below, desiccated, and protected from light.

General best practices for peptide storage include keeping lyophilized peptides in a cool, dry environment, protected from light and moisture. The peptide is soluble in water and buffered aqueous solutions. For specific temperature requirements and reconstitution protocols, consult the applicable product documentation or contact Core Peptides for the applicable storage specifications.

Research Considerations

Researchers incorporating Prostamax into their studies should be aware of several important considerations:

• Evidence Limitations: Prostamax has limited human clinical evidence. The single PubMed-indexed canonical citation is a 2004 study by Khavinson and colleagues. The peptide has not been tested in human clinical trials, and no clinical trials are registered on ClinicalTrials.gov.
• Experimental Status: Researchers consider Prostamax an experimental compound. Therefore, findings should be interpreted within the context of early-stage research.
• Model Differences: Results from cell cultures, organotypic explant cultures, and preclinical models may not translate directly to complex biological outcomes.
• Regulatory Status: Prostamax is not FDA-approved and is intended for laboratory research use only.
• Quality Considerations: Researchers should verify the quality and identity of their Prostamax through appropriate analytical methods.
• Mechanistic Context: Prostamax’s proposed mechanisms involve chromatin remodeling, epigenetic regulation, and tissue-specific gene modulation. Researchers should consider appropriate experimental approaches to investigate these pathways.
• Source Lineage: Essentially all published research originates from Khavinson’s group and affiliated institutions, with no independent Western replication.
• Tissue Specificity: Prostamax demonstrates tissue-specific effects on prostate-derived experimental systems. Researchers should consider this specificity when designing experiments.

Researchers who buy Prostamax in Switzerland should ensure their studies include appropriate controls and interpret findings with scientific rigor.

Frequently Asked Questions About Prostamax

What is Prostamax?

Prostamax is a synthetic tetrapeptide bioregulator with the amino acid sequence Lys-Glu-Asp-Pro (KEDP), developed within the Khavinson peptide research program as a prostate-tissue-targeted bioregulator.

What is Prostamax researched for?

Researchers primarily investigate Prostamax for its effects on prostate tissue-specific gene expression, chromatin remodeling, epigenetic regulation, and age-related cellular changes.

What is the amino acid sequence of Prostamax?

The amino acid sequence of Prostamax is Lys-Glu-Asp-Pro (KEDP).

What is the molecular weight of Prostamax?

The molecular weight of Prostamax is approximately 487.50 g/mol.

What is the molecular formula of Prostamax?

The molecular formula of Prostamax is C20H33N5O9.

Is Prostamax a Khavinson peptide?

Yes, Prostamax belongs to the Khavinson peptide series—a family of short-chain peptide bioregulators developed through research on tissue-specific regulators.

What is the proposed mechanism of Prostamax?

Prostamax is proposed to act at the chromatin level to modulate tissue-specific gene-expression patterns through chromatin decondensation, deheterochromatinization, and epigenetic regulation.

Does Prostamax have human clinical evidence?

Prostamax has limited human clinical evidence. The single PubMed-indexed canonical citation is a 2004 study by Khavinson and colleagues. The peptide has not been tested in human clinical trials.

Is Prostamax FDA-approved?

Prostamax is not FDA-approved. It is intended for laboratory research use only and is not approved for human consumption or therapeutic use.

Can I buy Prostamax in Switzerland?

Yes, researchers can buy Prostamax in Switzerland from Core Peptides for laboratory research purposes.

What is the primary research category for Prostamax?

Prostamax belongs to the Cellular Research & Signaling category, with secondary relevance to Anti-Aging & Longevity research.

What related peptides are studied alongside Prostamax?

Related peptides from the Khavinson series include Vesugen (KED), Pancragen (KEDW), Livagen (KEDA), Vilon (KE), and Epithalon (AEDG).

What is the purity of Core Peptides’ Prostamax?

Core Peptides provides Prostamax with a purity of ≥99% as verified by HPLC analysis.

How should Prostamax be stored?

Prostamax should be stored lyophilized at -20°C or below, desiccated, and protected from light.

What is the difference between Prostamax and Vesugen?

Prostamax is Lys-Glu-Asp-Pro (KEDP) targeting prostate tissue, while Vesugen is Lys-Glu-Asp (KED) targeting vascular-endothelial tissue. Vesugen shares the N-terminal three residues of Prostamax.

Related Research Peptides

Researchers interested in Prostamax may also find the following related peptides relevant to their work:

• Vesugen – A Khavinson tripeptide (KED) targeting vascular-endothelial tissue
• Pancragen – A Khavinson tetrapeptide (KEDW) targeting pancreatic tissue
• Livagen – A Khavinson tetrapeptide (KEDA) targeting liver tissue
• Vilon – A Khavinson dipeptide (KE) targeting thymus/immune system
• Epithalon – A Khavinson tetrapeptide (AEDG) targeting pineal gland

For a comprehensive selection of research peptides in Switzerland, explore the Core Peptides catalog.

Explore Cellular Research & Signaling Peptides

Prostamax is part of our Cellular Research & Signaling category, which features a range of research peptides investigated for their effects on cellular function, gene expression, and signaling pathways. Browse our selection to find the right peptides for your laboratory research.

Explore Related Research Categories

Researchers may also find the following related categories relevant to Prostamax research:

• Anti-Aging & Longevity – Peptides investigated for age-related cellular research applications
• Cognitive & Nootropic Peptides – Peptides studied for neurological and cognitive research
• Healing & Regeneration Peptides – Peptides investigated for tissue repair and regeneration

Further Research

Researchers interested in learning more about Prostamax and related peptides should consult the primary scientific literature. Key areas of investigation include chromatin remodeling, epigenetic regulation, prostate tissue bioregulation, and tissue-specific gene expression. The PubMed database is an excellent resource for accessing peer-reviewed research articles on these topics.

Research Disclaimer

Core Peptides supplies Prostamax as a research peptide for laboratory research purposes only. All information provided is for educational and scientific reference purposes only and does not constitute medical advice. Researchers are responsible for ensuring compliance with all applicable laws and regulations governing the use of research peptides in their jurisdiction, including Switzerland.